~~<i id='0EF116BAE4'><strike id='0EF116BAE4'><tt id='0EF116BAE4'><pre id='0EF116BAE4'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

fashion

author：knowledge 2025-09-27 10:04:58 - browse：9733

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

hotspot

focus

hotspot

Wikipedia

focus

entertainment

NewYork-PresbyterianHospitalreceived$631millionfromtheCovid-19ProviderReliefFund.CindyOrd/GettyImage

WSS

At ASCO, AstraZeneca reports strong data for breast cancer drug

Shifting the focus from loneliness to social health

Change Healthcare can notify patients about the breach, HHS says

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

At ASCO, AstraZeneca reports strong data for breast cancer drug

Wikipedia

fashion

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Medicare Advantage coverage denials need scrutiny, senators say

In age of alternative facts, a scholarly course on calling out crap

Ionis drug prevents swelling attacks due to hereditary angioedema

Sports medicine is finally prioritizing gender equality

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Malaria cases in Florida and Texas: Here’s what you need to know

Life science postdocs should get big pay hike, NIH panel says

As demand for Covid shots wanes, Moderna seeks its next success

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

focus

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Woman returns to dialysis after doctors remove transplanted pig kidney

BMI, flaws aside, is found to be useful estimate of body fat in youth

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Profiling embryos to choose those with higher IQs is almost a reality

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

hotspot

Wikipedia

focus

entertainment